PDS announces Canadian IP Office has allowed patent for Versamune, PDS0301

PDS Biotechnology announced the Canadian Intellectual Property, IP, Office has allowed patent number 2,876,656 titled, “Cationic Lipid Vaccine Combinations and Methods of Use,” governing composition of matter and uses for Versamune in combination with PDS0301. The intellectual property provides broad protection for treatments utilizing Versamune based therapies, including PDS0101, in combination with PDS0301 as a potential treatment for cancer. This patent expands PDS Biotech’s market coverage and adds to the world-wide patent portfolio including the patent granted by the United States Patent and Trademark Office, U.S. Patent No. 11,401,306, covering the combination of Versamune and cytokines including Interleukin 12. “This newly allowed patent adds to the intellectual property governing Versamune(R) based therapies in combination with PDS0301, which we believe represent a potentially transformative treatment approach for advanced cancer patients,” said Dr. Frank Bedu-Addo, CEO of PDS Biotech. “Possessing multilayered IP for our immunotherapies is an important value driver for PDS Biotech and is a key component of our business strategy. We anticipate that Canada will constitute an important market as we begin our commercialization and partnership strategies.”